PROCEPT BioRobotics Corporation Financial Results Announcement
PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a leader in surgical robotics, is set to unveil its financial results for the second quarter of 2025 after the market closes. The announcement will be made on the specified date, and the company’s management team will conduct a conference call to discuss these results.
Details of the Upcoming Conference Call
The conference call is designed for investors and stakeholders interested in the latest updates from PROCEPT BioRobotics. The management will address key highlights and answer questions. Those who wish to participate can find important connection details as the date approaches.
Accessing the Live Webcast
A live audio broadcast of the conference call will be available on the Investors section of PROCEPT BioRobotics’ official website. Investors are encouraged to tune in to gain insights into the company's performance and prospects.
Post-Event Access
If you cannot attend the live session, don't worry. The company will also provide an archived recording of the call, accessible from its website for at least 90 days following the event. This ensures that all interested parties have the chance to catch up on the important discussions and announcements.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation is dedicated to advancing the treatment of Benign Prostatic Hyperplasia (BPH) through innovative surgical robot solutions. The company is best known for the AQUABEAM and HYDROS robotic systems, which utilize advanced technology to deliver Aquablation therapy, providing consistent and lasting relief for men experiencing lower urinary tract symptoms. Their approach caters to a broad range of patients, regardless of prostate size or surgeon expertise, marking a significant advance in urological treatment.
The Significance of BPH Treatment
BPH remains one of the most common ailments affecting men, impacting 40 million men in the United States alone. PROCEPT BioRobotics has amassed a wealth of clinical data supporting the efficacy of Aquablation therapy, backed by over 150 peer-reviewed publications. The commitment to clinical excellence is evident in their approach to treatment, focusing on positive long-term outcomes.
Company Commitment and Mission
At the heart of PROCEPT BioRobotics' mission is a partnership with urologists to transform patient care. By continuously investing in pioneering technology and innovative solutions, the organization aims to deliver treatments that not only enhance patient outcomes but also improve overall value within the healthcare sphere.
Investor Contact Information
For inquiries regarding the latest financial results and corporate developments, reach out to:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com
Frequently Asked Questions
When will PROCEPT report its second quarter 2025 results?
PROCEPT will announce its financial results after the market closes on the specified date.
How can investors listen to the conference call?
Investors can tune in via the live audio broadcast accessible through the company’s Investors section on its website.
Will there be a recording available for the conference call?
Yes, an archived recording will be provided on the website for a minimum of 90 days post-event.
What specific solutions does PROCEPT BioRobotics offer?
PROCEPT specializes in advanced surgical robotics, including the AQUABEAM and HYDROS systems, which deliver Aquablation therapy for BPH treatment.
Who can I contact for more information?
For further inquiries, you can reach out to Matt Bacso, the VP of Investor Relations and Business Operations.
